These results also indicate that the AQP9 generation in APL subjects is a prognostic biomarker for the positive effect of ATO administration, as AQP9 has a fundamental relevance in multiple arsenite-mediated action on normal and leukemic cells. This evidence concerns the gene AQP9 and acute promyelocytic leukemia.